Frequency of skeletal metastasis on 18F-fluorodeoxyglucose positron emission tomography/computed tomography with negative computed tomography at Institute of Nuclear Medicine and Oncology

Authors

  • Mariam Fayyaz Medical Imaging Technologist, Department of Allied Health Sciences, FMH College of Medicine and Dentistry, University of Lahore, Lahore, Punjab, Pakistan https://orcid.org/0000-0002-7945-5301
  • Muhammad Numair Younis Consultant Nuclear Physician, Department of Nuclear Medicine, Institute of Nuclear Medicine and Oncology, University of Lahore, Lahore, Punjab, Pakistan https://orcid.org/0000-0002-3853-8805
  • Sheikh Danial Hanan Senior Demonstrator, Department of Allied Health Sciences, FMH College of Medicine and Dentistry, University of Lahore, Lahore, Punjab, Pakistan https://orcid.org/0000-0001-7500-4768
  • Syed Zain Ul Abidin Assistant Professor, Department of Allied Health Sciences, University of Lahore, Lahore, Punjab, Pakistan
  • Rimsha Badar Demonstrator, Department of Allied Health Sciences, FMH College of Medicine and Dentistry, University of Lahore, Lahore, Punjab, Pakistan https://orcid.org/0000-0002-8211-5682
  • Muhammad Waseem Akram CT Radiographer, University of Oxford-JR Site Level 1 Radiology, Oxford University Hospital, Oxford, England, United Kingdom https://orcid.org/0000-0002-1011-1375

DOI:

https://doi.org/10.3126/ajms.v13i11.45979

Keywords:

18 F-fluorodeoxyglucose positron emission tomography/computed tomography; Computed tomography negative; Positron emission tomography positive; Skeletal metastasis

Abstract

Background: Skeletal metastasis (SM) with skeletal related events (SREs) occurs in up to 70% of breast cancer and more than 50% of malignant tumors. Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) used to characterize the metabolic, anatomic, and morphologic status of suspected bone lesions. SMs are detected using multiple modalities; however, FDG PET/CT may offer a single investigation to detect SM combining the strength of functional imaging and radiological imaging simultaneously.

Aims and Objectives: This study was to assess the frequency of SM on 18F-FDG PET/CT with negative CT at Institute of Nuclear Medicine and Oncology (INMOL).

Materials and Methods: This cross-sectional study included a sample of total 50 patients with SM of known primary malignancies who underwent 18F-FDG PET/CT scan at INMOL Cancer Hospital, Lahore.

Results: Of the 50 patients, we discovered the concordant findings between PET and CT as both PET+/CT+ in 38 patients (76%) whereas in 12 patients (24%) with PET+/CT- findings were discordant. CT was unable to detect SM in at least 12 patients. The maximum standardized uptake value (SUVmax) of SM in patients with negative CT found to be slightly higher as 5.2±4.1 (range: 2.5–7.8) than in patients with positive CT finding as 4.8±2.8 (range: 3.9–5.8) with P=0.76. P-value is insignificant this means that high SUV is not typical or conclusive evidence of metastasis.

Conclusion: Despite limited data, this study has demonstrated high concordance between FDG PET and CT scan in detecting SM. Furthermore, the study has shown that 18F-FDG PET appears to have slightly better detection efficiency as compared to CT for identification of SM which is statistically insignificant. The study demonstrated that SUV is higher in PET and CT discordant cases; however, it does not provide conclusive information favoring diagnosis of SM.

Downloads

Download data is not yet available.
Abstract
112
PDF
83

Downloads

Published

2022-11-01

How to Cite

Fayyaz, M., Muhammad Numair Younis, Sheikh Danial Hanan, Syed Zain Ul Abidin, Rimsha Badar, & Muhammad Waseem Akram. (2022). Frequency of skeletal metastasis on 18F-fluorodeoxyglucose positron emission tomography/computed tomography with negative computed tomography at Institute of Nuclear Medicine and Oncology. Asian Journal of Medical Sciences, 13(11), 59–63. https://doi.org/10.3126/ajms.v13i11.45979

Issue

Vol. 13 No. 11 (2022)

Section

Original Articles

License

Copyright (c) 2022 Asian Journal of Medical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).